Literature DB >> 6149592

Dopamine and non-dopamine psychoses.

D L Garver, F Zemlan, J Hirschowitz, R Hitzemann, M L Mavroidis.   

Abstract

The time course of antipsychotic response following the initiation of an antipsychotic drug and functional dopamine receptor sensitivity were explored in a cohort of recently admitted psychotic (mood-incongruent) patients. The distribution of the latencies of antipsychotic response suggested at least two populations. Rapid responders (RRs) had 60% reduction of baseline psychotic symptoms by a mean of 5.5 days of drug treatment. Delayed/nonresponders required 2-7 weeks for a similar reduction of psychotic symptoms. The sensitivity of postsynaptic dopamine receptors was explored using a neuroendocrine probe: growth hormone response to the dopamine agonist, apomorphine (AP). RRs had an exaggerated growth hormone response to AP in comparison to delayed/nonresponders (P less than 0.05). Exaggerated sensitivity of postsynaptic dopamine receptors and rapid antipsychotic response following dopamine receptor blockade in RRs suggest a true functional dopamine hypersensitivity disorder in the RR group. In contrast, lower postsynaptic receptor sensitivity (as reflected by lower growth hormone response to AP) and failure of early response following dopamine receptor blockade focus attention away from dopamine hyperactivity as a relevant etiologic mechanism in delayed/nonresponders. Response rates to neuroleptic drugs and neuroendocrine probes of receptor sensitivity may separate two or more etiologically distinct diseases with schizophrenic-like symptoms.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149592     DOI: 10.1007/bf00432044

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  10 in total

1.  Dopamine receptors and average clinical doses.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-10-29       Impact factor: 47.728

2.  Drugs, neurotransmitters, and schizophrenia.

Authors:  S H Snyder; S P Banerjee; H I Yamamura; D Greenberg
Journal:  Science       Date:  1974-06-21       Impact factor: 47.728

3.  Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity.

Authors:  B S Bunney; A A Grace
Journal:  Life Sci       Date:  1978-10-23       Impact factor: 5.037

4.  A checklist for the diagnosis of schizophrenia.

Authors:  B M Astrachan; M Harrow; D Adler; L Brauer; A Schwartz; C Schwartz; G Tucker
Journal:  Br J Psychiatry       Date:  1972-11       Impact factor: 9.319

5.  Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons.

Authors:  F J White; R Y Wang
Journal:  Science       Date:  1983-09-09       Impact factor: 47.728

6.  Therapeutic blood levels of fluphenazine: plasma or RBC determinations?

Authors:  M L Mavroidis; D R Kanter; J Hirschowitz; D L Garver
Journal:  Psychopharmacol Bull       Date:  1984

7.  Clinical relevance of thiothixene plasma levels.

Authors:  M L Mavroidis; D R Kanter; J Hirschowitz; D L Garver
Journal:  J Clin Psychopharmacol       Date:  1984-06       Impact factor: 3.153

8.  Clinical response and plasma haloperidol levels in schizophrenia.

Authors:  M L Mavroidis; D R Kanter; J Hirschowitz; D L Garver
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

9.  Postsynaptic supersensitivity in schizophrenia.

Authors:  G N Pandey; D L Garver; C Tamminga; S Ericksen; S I Ali; J M Davis
Journal:  Am J Psychiatry       Date:  1977-05       Impact factor: 18.112

10.  Evidence for coexistence of dopamine and CCK in meso-limbic neurones.

Authors:  T Hökfelt; J F Rehfeld; L Skirboll; B Ivemark; M Goldstein; K Markey
Journal:  Nature       Date:  1980-06-12       Impact factor: 49.962

  10 in total
  2 in total

1.  A quantitative magnetic resonance imaging study of patients with schizophrenia.

Authors:  Y Kawasaki; Y Maeda; K Urata; M Higashima; N Yamaguchi; M Suzuki; T Takashima; Y Ide
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

2.  On the selection of mice for haloperidol response and non-response.

Authors:  R Hitzemann; K Dains; C M Bier-Langing; N R Zahniser
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.